Friday, February 02, 2024
Graviton Bioscience, a clinical-stage biotechnology firm focused on developing therapies that inhibit Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2), has recently secured a strategic investment from Sanofi, a leading pharmaceutical company. The agreement grants Sanofi the right of first negotiation to license compounds across various indications, including immunological and metabolic syndrome indications, thereby advancing the progress of ROCK2 inhibitor treatments.
ROCK2, categorized as an effector of the small GTPase Rho and belonging to the AGC family of kinases, is implicated in the pathology of several diseases, ranging from metabolic and autoimmune to inflammatory and neurologic disorders with insufficient or no existing treatments.
Graviton expressed enthusiasm about Sanofi joining as a strategic partner, emphasizing the alignment of their dedication with Graviton's vision. He stated that this investment marks a significant milestone in advancing and commercializing ROCK2 inhibitors, offering hope for patients on a global scale.
Sanofi, underscored the company's commitment to innovative therapies and providing patients with novel medicines and vaccines. He expressed confidence in Graviton's scientific expertise, foreseeing its potential to significantly enhance the therapeutic landscape.